Targeted Medical Pharma launches e-prescribe platform for Theramine

The secure online e-prescribing portal is available to healthcare providers in the US, interested in a clinically validated, peer reviewed, non-pharmacologic alternative to narcotic and NSAID pain medications for patients suffering from pain syndromes.

Theramine is a medical food indicated for the dietary management of pain syndromes, and has been the subject of two double-blind, randomized, multi-center trials, which compared Theramine to low dose naproxen and ibuprofen.

A total of 256 subjects participated in the two studies across 10 independent sites that were randomized for treatment to receive Theramine alone (two capsules twice daily), NSAID or a combination of both. In both studies, Theramine showed a statistically significant reduction in inflammation and improvement in low back pain than either naproxen at 250mg daily or ibuprofen at 400mg daily.

Targeted Medical Pharma CEO and chief science officer Dr William Shell noted clinical evidence suggests that by addressing the increased amino acid requirements of pain syndromes you can significantly improve pain perception and reduce inflammation.

"Theramine is a very useful clinical tool for physicians interested in managing pain and inflammation without the GI or cardiovascular side effects associated with NSAIDs or the addictive potential of narcotics," Dr Shell added.